Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisolone + vitamin E is a combination of two agents: prednisolone, a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, and vitamin E (α-tocopherol), a fat-soluble antioxidant. Prednisolone acts primarily by binding to the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses. Vitamin E functions as an antioxidant, protecting cell membranes from oxidative damage by neutralizing free radicals. This combination has been studied in preclinical models for its potential to mitigate some adverse effects of chronic prednisolone therapy—such as oxidative stress and impaired phagocyte function—by leveraging the antioxidative properties of vitamin E. There is no evidence that this specific combination is marketed as a fixed-dose pharmaceutical product; it may be used in research or clinical practice as co-administered agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prednisolone + vitamin E.